Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.
Chugai Pharmaceutical Trading Down 2.1%
Shares of OTCMKTS:CHGCY opened at $27.52 on Tuesday. Chugai Pharmaceutical has a 12-month low of $19.50 and a 12-month high of $31.26. The stock has a market capitalization of $90.57 billion, a price-to-earnings ratio of 34.40 and a beta of 0.63. The stock has a fifty day simple moving average of $26.72 and a two-hundred day simple moving average of $24.39.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Read More
- Five stocks we like better than Chugai Pharmaceutical
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
